Analysis of circulating ceramides and hexosylceramides in patients with coronary artery disease and type II diabetes mellitus.

Background: Cardiovascular disease (CVD) remains the leading cause of death worldwide. The main driving force behind this association is coronary artery disease (CAD), the manifestation of atherosclerosis in the coronary circulation. Cornerstones in the development of CAD are pathologies in lipid metabolism.